Longterm Clinical Outcomes in 420 Patients with Psoriatic Arthritis Taking Anti-tumor Necrosis Factor Drugs in Real-world Settings

REFERENCES

1. 1.↵
   1. Ash Z,
   2. Gaujoux-Viala C,
   3. Gossec L,
   4. Hensor EM,
   5. FitzGerald O,
   6. Winthrop K,
   7. et al.

   A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319–26.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Gladman DD,
   2. Mease PJ,
   3. Ritchlin CT,
   4. Choy EH,
   5. Sharp JT,
   6. Ory PA,
   7. et al.

   Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476–88.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Goulabchand R,
   2. Mouterde G,
   3. Barnetche T,
   4. Lukas C,
   5. Morel J,
   6. Combe B

   . Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 2014;73:414–9.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Heiberg MS,
   2. Kaufmann C,
   3. Rødevand E,
   4. Mikkelsen K,
   5. Koldingsnes W,
   6. Mowinckel P,
   7. et al.

   The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis 2007;66:1038–42.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Kavanaugh A,
   2. Krueger GG,
   3. Beutler A,
   4. Guzzo C,
   5. Zhou B,
   6. Dooley LT,
   7. et al.

   Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007;66:498–505.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Mease PJ,
   2. Goffe BS,
   3. Metz J,
   4. VanderStoep A,
   5. Finck B,
   6. Burge DJ

   . Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385–90.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Glintborg B,
   2. Østergaard M,
   3. Dreyer L,
   4. Krogh NS,
   5. Tarp U,
   6. Hansen MS,
   7. et al.

   Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011;63:382–90.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Kristensen LE,
   2. Gülfe A,
   3. Saxne T,
   4. Geborek P

   . Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008;67:364–9.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Saougou I,
   2. Markatseli TE,
   3. Papagoras C,
   4. Voulgari PV,
   5. Alamanos Y,
   6. Drosos AA

   . Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum 2011;40:398–406.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Taylor W,
    2. Gladman D,
    3. Helliwell P,
    4. Marchesoni A,
    5. Mease P,
    6. Mielants H;
    7. CASPAR Study Group

    . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Scarpa R,
    2. Atteno M,
    3. Lubrano E,
    4. Provenzano G,
    5. D’Angelo S,
    6. Spadaro A,
    7. et al.

    The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin Rheumatol 2011;30:1063–7.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Gladman DD,
    2. Bombardier C,
    3. Thorne C,
    4. Haraoui B,
    5. Khraishi M,
    6. Rahman P,
    7. et al.

    Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial. J Rheumatol 2011;38:1355–62.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Fransen J,
    2. Antoni C,
    3. Mease PJ,
    4. Uter W,
    5. Kavanaugh A,
    6. Kalden JR,
    7. et al.

    Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006;65:1373–8.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Iannone F,
    2. Lopriore S,
    3. Bucci R,
    4. Scioscia C,
    5. Anelli MG,
    6. Notarnicola A,
    7. et al.

    Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA. Scand J Rheumatol 2015;44:192–9.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Fagerli KM,
    2. Lie E,
    3. van der Heijde D,
    4. Heiberg MS,
    5. Kalstad S,
    6. Rødevand E,
    7. et al.

    Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis 2013;72:1840–4.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Saad AA,
    2. Ashcroft DM,
    3. Watson KD,
    4. Symmons DP,
    5. Noyce PR,
    6. Hyrich KL;
    7. BSRBR

    . Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology 2010;49:697–705.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Fagerli KM,
    2. Lie E,
    3. van der Heijde D,
    4. Heiberg MS,
    5. Lexberg AS,
    6. Rødevand E,
    7. et al.

    The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014;73:132–7.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Soubrier AS,
    2. Bele-Philippe P,
    3. Cortet B,
    4. Ramdane-Sebbane N,
    5. Bacle-Boutry MA,
    6. Lemeunier L,
    7. et al.

    Treatment response, drug survival and safety of anti-tumour necrosis factor α therapy in 193 patients with psoriatic arthritis: a twelve-year “real life” experience. Joint Bone Spine 2015;82:31–7.

    OpenUrlCrossRefPubMed